Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
19#iSCLife®-CSD for Healing Poor After Uterus Injury
NCT03386708Phase 1Completed
- Sponsor
- Sclnow Biotechnology Co., Ltd.
- Start
- Oct 2018
- Primary completion
- Jun 2021
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of iSCLife I.V. Drip in Uterine rupture (UR), Intrauterine Adhesions (IUA) and cesarean scar defect (CSD), sponsored by Sclnow Biotechnology Co., Ltd. Primary endpoint: Intrauterine adhesion patients efficacy evaluation at 12 months. Started Oct 2018; status: completed.
02
Drugs
iSCLife I.V. Drip
03
Conditions
Uterine rupture (UR)Intrauterine Adhesions (IUA)cesarean scar defect (CSD)
Beyond the preview
Go deeper on NCT03386708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03386708.